PL2152867T3 - Sposoby wytwarzania czynnika X, aktywowanego czynnika X, inaktywowanego czynnika X i inaktywowanego czynnika Xa - Google Patents
Sposoby wytwarzania czynnika X, aktywowanego czynnika X, inaktywowanego czynnika X i inaktywowanego czynnika XaInfo
- Publication number
- PL2152867T3 PL2152867T3 PL08750714T PL08750714T PL2152867T3 PL 2152867 T3 PL2152867 T3 PL 2152867T3 PL 08750714 T PL08750714 T PL 08750714T PL 08750714 T PL08750714 T PL 08750714T PL 2152867 T3 PL2152867 T3 PL 2152867T3
- Authority
- PL
- Poland
- Prior art keywords
- factor
- inactivated
- methods
- preparing
- activated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6432—Coagulation factor Xa (3.4.21.6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21006—Coagulation factor Xa (3.4.21.6)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0710321.1A GB0710321D0 (en) | 2007-05-30 | 2007-05-30 | Method |
| PCT/GB2008/001810 WO2008145989A1 (en) | 2007-05-30 | 2008-05-29 | Methods for preparing factor x, activated factor x, inactivated factor x and inactivated factor xa, and pharmaceutical compositions comprising same |
| EP08750714A EP2152867B1 (en) | 2007-05-30 | 2008-05-29 | Methods for preparing Factor X, activated Factor X, inactivated Factor X and inactivated Factor Xa |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2152867T3 true PL2152867T3 (pl) | 2013-04-30 |
Family
ID=38289546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08750714T PL2152867T3 (pl) | 2007-05-30 | 2008-05-29 | Sposoby wytwarzania czynnika X, aktywowanego czynnika X, inaktywowanego czynnika X i inaktywowanego czynnika Xa |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8906366B2 (pl) |
| EP (1) | EP2152867B1 (pl) |
| JP (1) | JP5261478B2 (pl) |
| CA (1) | CA2687604C (pl) |
| DK (1) | DK2152867T3 (pl) |
| ES (1) | ES2400014T3 (pl) |
| GB (1) | GB0710321D0 (pl) |
| IL (1) | IL201931A (pl) |
| PL (1) | PL2152867T3 (pl) |
| PT (1) | PT2152867E (pl) |
| SI (1) | SI2152867T1 (pl) |
| WO (1) | WO2008145989A1 (pl) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2770077A1 (en) * | 2009-08-06 | 2011-02-10 | Ironwood Pharmaceuticals, Inc. | Formulations comprising linaclotide |
| SG191186A1 (en) * | 2010-12-15 | 2013-07-31 | Baxter Int | Eluate collection using conductivity gradient |
| AU2013365623B2 (en) * | 2012-12-20 | 2017-08-24 | Omrix Biopharmaceuticals Ltd. | Viral inactivated biological mixture |
| FR3000895B1 (fr) * | 2013-01-11 | 2017-02-24 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies Sa | Utilisation d'antidotes d'inhibiteurs de la coagulation indiques dans la prevention ou le traitement de pathologies thromboemboliques |
| AR102331A1 (es) | 2014-08-12 | 2017-02-22 | Baxalta Inc | Activación del factor x |
| FR3032621A1 (fr) | 2015-02-13 | 2016-08-19 | Lab Francais Du Fractionnement | Colle biologique et son utilisation comme medicament |
| EP3590528A1 (en) | 2018-07-06 | 2020-01-08 | Octapharma AG | Fx activation process and its use in the preparation of a fxa composition |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4481189A (en) | 1982-04-14 | 1984-11-06 | New York Blood Center Inc. | Process for preparing sterilized plasma and plasma derivatives |
| US4540573A (en) | 1983-07-14 | 1985-09-10 | New York Blood Center, Inc. | Undenatured virus-free biologically active protein derivatives |
| US4613501A (en) | 1984-12-21 | 1986-09-23 | New York Blood Center, Inc. | Inactivation of viruses in labile blood derivatives |
| GB8729822D0 (en) * | 1987-12-22 | 1988-02-03 | Central Blood Lab Authority | Chemical process |
| US5120537A (en) * | 1989-06-14 | 1992-06-09 | Oklahoma Medical Research Foundation | Factor xa based anticoagulant compositions |
| IT1262899B (it) * | 1992-03-27 | 1996-07-22 | Sclavo Spa | Processo per l'isolamento di fattore ix, fattore x e fattore ii altamente purificati dal complesso protrombinico o dal plasma umano |
| US5219995A (en) * | 1992-07-14 | 1993-06-15 | Alpha Therapeutic Corporation | Plasma fraction purification |
| US5589571A (en) * | 1994-10-28 | 1996-12-31 | Cor Therapeutics, Inc. | Process for production of inhibited forms of activated blood factors |
| AT405516B (de) * | 1997-02-27 | 1999-09-27 | Immuno Ag | Faktor x-analoge mit modifizierter proteasespaltstelle |
| AU2001257893A1 (en) * | 2000-01-13 | 2001-07-24 | Baxter International Inc. | Multiple inactivated blood factor anticoagulant composition |
| SI1478394T1 (sl) * | 2002-02-27 | 2008-12-31 | Immunex Corp | STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM |
| SE0203551D0 (sv) * | 2002-12-02 | 2002-12-02 | Biovitrum Ab | Prothrombin purification |
| EP2360171A1 (en) * | 2004-12-23 | 2011-08-24 | Novo Nordisk Health Care AG | Reduction of the content of protein contaminants in compositions comprising a vitamin K-dependent protein of interest |
-
2007
- 2007-05-30 GB GBGB0710321.1A patent/GB0710321D0/en not_active Ceased
-
2008
- 2008-05-29 PL PL08750714T patent/PL2152867T3/pl unknown
- 2008-05-29 CA CA2687604A patent/CA2687604C/en active Active
- 2008-05-29 DK DK08750714.1T patent/DK2152867T3/da active
- 2008-05-29 US US12/601,930 patent/US8906366B2/en active Active
- 2008-05-29 SI SI200830884T patent/SI2152867T1/sl unknown
- 2008-05-29 PT PT87507141T patent/PT2152867E/pt unknown
- 2008-05-29 WO PCT/GB2008/001810 patent/WO2008145989A1/en not_active Ceased
- 2008-05-29 EP EP08750714A patent/EP2152867B1/en active Active
- 2008-05-29 ES ES08750714T patent/ES2400014T3/es active Active
- 2008-05-29 JP JP2010509888A patent/JP5261478B2/ja active Active
-
2009
- 2009-11-04 IL IL201931A patent/IL201931A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| US8906366B2 (en) | 2014-12-09 |
| WO2008145989A1 (en) | 2008-12-04 |
| ES2400014T3 (es) | 2013-04-05 |
| CA2687604A1 (en) | 2008-12-04 |
| GB0710321D0 (en) | 2007-07-11 |
| IL201931A0 (en) | 2011-08-01 |
| IL201931A (en) | 2013-04-30 |
| SI2152867T1 (sl) | 2013-03-29 |
| PT2152867E (pt) | 2012-12-17 |
| JP5261478B2 (ja) | 2013-08-14 |
| DK2152867T3 (da) | 2013-01-14 |
| JP2010528096A (ja) | 2010-08-19 |
| EP2152867A1 (en) | 2010-02-17 |
| AU2008257222A1 (en) | 2008-12-04 |
| AU2008257222B2 (en) | 2013-05-16 |
| US20100233149A1 (en) | 2010-09-16 |
| CA2687604C (en) | 2016-04-12 |
| EP2152867B1 (en) | 2012-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL184701A0 (en) | Atm activated by cell-phone | |
| PL2046405T3 (pl) | Biomateriały, ich wytwarzanie i zastosowanie | |
| IL217717A0 (en) | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof | |
| GB0917044D0 (en) | Agents, uses and methods | |
| HUE046118T2 (hu) | Csontserkentõ-alakító eszköz, rendszer és eljárás | |
| ZA201003411B (en) | Air filters arrangements; assembles; and, methods | |
| GB0917054D0 (en) | Agents, uses and methods | |
| IL202300A0 (en) | 17beta-cyano-18a-homo-19-nor-androst-4-ene derivative, use thereof and medicaments containing said derivative | |
| IL198915A0 (en) | Elastodynamic energy accumulator-regulator | |
| EP2235854A4 (en) | ADAPTER, DEVICE AND METHOD | |
| EP2307344A4 (en) | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, PREPARATION AND USE THEREOF | |
| GB0713012D0 (en) | Received message verification | |
| IL187624A0 (en) | Secure messaging | |
| GB0718263D0 (en) | Polysaccharide derived mesoporous materials | |
| SI2152867T1 (sl) | Postopki za pripravo faktorja X, aktiviranega faktorja X, inaktiviranega faktorja X in inaktiviranega faktorja Xa | |
| GB0820231D0 (en) | Airbagmodul, airbagmodulanordung und befestigungsverfahren | |
| GB0719592D0 (en) | Compound, use and method | |
| GB0616306D0 (en) | Vaccines | |
| IL209718A0 (en) | Substituted 7-sulfanylmethyl, 7-sulfinylmethyl and 7-sulfonylmethyl indoles and use thereof | |
| GB2462000B (en) | Security room | |
| ZA201000187B (en) | 17b-cyano-19-nor-androst-4-ene derivative,use thereof and medicaments containing said derivative | |
| EP2479521A4 (en) | Heater unit, and air purifier including same | |
| GB0703763D0 (en) | Bone-replacement materials,methods and devices | |
| SI2376479T1 (sl) | Substituirani furankarboksamidi in njihova uporaba | |
| ZA201000186B (en) | 17b-cyano-19-androst-4-ene derivative,use thereof and medicaments containing said derivative |